Journal: Redox Biology

Article Title: Mitochondrial superoxide sustains a senescence-like phenotype in PARP- inhibited ovarian cancer cells by stabilizing HIF1α

doi: 10.1016/j.redox.2026.104158

Figure Lengend Snippet: PARP inhibitor induces senescence-like phenotype in vivo. (A) Schematic diagram for the treatment paradigm. OVCAR3 cells were subcutaneously transplanted in NCG mice. Mice were randomized into two treatment groups: vehicle (DMSO, n = 3), 20 mg/kg Rucaparib (PARPi, n = 4) (given daily by intraperitoneal injection). (B) Growth curves of tumors in mice. Tumor volumes were measured every day. (C) Image of tumors and tumor weights in mice. (D) SA-β-gal staining and quantification in tumor tissues. Scale bar: 50 μm. (E) Flow cytometric analysis of SPiDER-β-gal in single cell suspension of tumor tissues. (F) Immunofluorescence staining of Tomm20 and quantification in tumor tissues. Scale bar: 50 μm. (G) Flow cytometric analysis of mitochondrial content in single cell suspension of tumor tissues. (H) Representative IHC images of HIF1α expression and quantification in tumor tissues. Scale bar: 50 μm. (I) Flow cytometric analysis of HIF1α in single cell suspension of tumor tissues. Data presented as mean ± S.D. The statistical differences between the two groups were analyzed by two-sided unpaired Student's t-test (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001).

Article Snippet: SA β-galactosidase activity was measured by senescence-associated β-galactosidase staining kit (Beyotime, C0602) or SPiDER-β-gal reagent (Dojindo, SG02).

Techniques: In Vivo, Injection, Staining, Single Cell, Suspension, Immunofluorescence, Expressing

Journal: Redox Biology

Article Title: Mitochondrial superoxide sustains a senescence-like phenotype in PARP- inhibited ovarian cancer cells by stabilizing HIF1α

doi: 10.1016/j.redox.2026.104158

Figure Lengend Snippet: MitoQ attenuates senescence-like phenotype in vivo. (A) Schematic treatment diagram. OVCAR3 cells were subcutaneously transplanted in NCG mice. Mice were randomized into four treatment groups: vehicle (DMSO, n = 5), 2 mg/kg MitoQ alone (n = 5) (given every other day by oral gavage), 20 mg/kg Rucaparib alone (n = 5) (given daily by intraperitoneal injection) or 20 mg/kg Rucaparib plus 2 mg/kg MitoQ (n = 5). (B) Growth curves of tumors in mice. Tumor volumes were measured every day. (C) Image of tumors and tumor weights in mice. (D) SA-β-gal staining and (E) quantification in tumor tissues. Scale bar: 50 μm. (F) Flow cytometric analysis of SPiDER-β-gal in single cell suspension of tumor tissues. (G) Representative IHC images showing the HIF1α. Scale bar: 50 μm. (H) Quantification of HIF1α expression in tumor tissues. (I) Flow cytometric analysis of HIF1α in single cell suspension of tumor tissues. (J) Lactate levels in tumor tissues. (K) A schematic model. In ovarian cancer cells, PARP inhibitors induce senescence-like phenotype. Cells undergo metabolic reprogramming through the mtROS-HIF1α axis to sustain survival. Data presented as mean ± S.D. ANOVA was used to compare significant differences among multiple experimental groups (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001).

Article Snippet: SA β-galactosidase activity was measured by senescence-associated β-galactosidase staining kit (Beyotime, C0602) or SPiDER-β-gal reagent (Dojindo, SG02).

Techniques: In Vivo, Injection, Staining, Single Cell, Suspension, Expressing